Loading...
•
Dec 31, 2019
Regeneron Q4 2019 Earnings Report
Regeneron's Q4 2019 financial results were announced, featuring a 13% increase in revenue and significant advancements in the clinical pipeline.
Key Takeaways
Regeneron reported a strong fourth quarter in 2019, with revenues increasing by 13% to $2.17 billion. GAAP diluted EPS was $6.93, and non-GAAP diluted EPS was $7.50. The company highlighted commercial growth, pipeline progress, and positive financial results, with a focus on driving growth with EYLEA, Dupixent, and Libtayo in 2020.
Total revenues increased by 13% to $2.17 billion compared to Q4 2018.
EYLEA U.S. net sales increased by 13% to $1.22 billion compared to Q4 2018.
Dupixent global net sales increased by 136% to $752 million compared to Q4 2018.
GAAP diluted EPS was $6.93, and non-GAAP diluted EPS was $7.50.
Revenue by Segment
Forward Guidance
Regeneron will provide financial guidance for full year 2020 by the end of the first quarter of 2020, following the announcement regarding the intent to restructure the antibody collaboration for Kevzara and Praluent with Sanofi.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...